[go: up one dir, main page]

NO992273L - Anvendelse av et promedikament med en struktur svarende til den av en biopÕvirkende forbindelse som er et uracil eller en uracilbaseanalog - Google Patents

Anvendelse av et promedikament med en struktur svarende til den av en biopÕvirkende forbindelse som er et uracil eller en uracilbaseanalog

Info

Publication number
NO992273L
NO992273L NO992273A NO992273A NO992273L NO 992273 L NO992273 L NO 992273L NO 992273 A NO992273 A NO 992273A NO 992273 A NO992273 A NO 992273A NO 992273 L NO992273 L NO 992273L
Authority
NO
Norway
Prior art keywords
uracil
prodrug
structure similar
bioactive compound
base analogue
Prior art date
Application number
NO992273A
Other languages
English (en)
Other versions
NO308884B1 (no
NO992273D0 (no
Inventor
Yung-Chi Cheng
Chien-Neng Chang
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of NO992273D0 publication Critical patent/NO992273D0/no
Publication of NO992273L publication Critical patent/NO992273L/no
Publication of NO308884B1 publication Critical patent/NO308884B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO992273A 1991-05-15 1999-05-11 Anvendelse av 5-halo-2-pyrimidin-deoksyribose eller 5-halo- pyrimidinon for fremstilling av et medikament for behandling av kreft NO308884B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70146291A 1991-05-15 1991-05-15
US82947492A 1992-02-03 1992-02-03
PCT/US1992/004142 WO1992020816A1 (en) 1991-05-15 1992-05-15 Determination of prodrugs metabolizable by the liver and therapeutic use thereof

Publications (3)

Publication Number Publication Date
NO992273D0 NO992273D0 (no) 1999-05-11
NO992273L true NO992273L (no) 1999-05-11
NO308884B1 NO308884B1 (no) 2000-11-13

Family

ID=27106792

Family Applications (2)

Application Number Title Priority Date Filing Date
NO934059A NO306850B1 (no) 1991-05-15 1993-11-09 Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom
NO992273A NO308884B1 (no) 1991-05-15 1999-05-11 Anvendelse av 5-halo-2-pyrimidin-deoksyribose eller 5-halo- pyrimidinon for fremstilling av et medikament for behandling av kreft

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO934059A NO306850B1 (no) 1991-05-15 1993-11-09 Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom

Country Status (13)

Country Link
US (1) US5728684A (no)
EP (1) EP0586523A4 (no)
JP (1) JPH06507902A (no)
KR (1) KR100245252B1 (no)
AU (1) AU673803B2 (no)
BG (1) BG98217A (no)
CA (1) CA2103050A1 (no)
HU (1) HUT67392A (no)
IE (1) IE921581A1 (no)
IL (1) IL101879A (no)
NO (2) NO306850B1 (no)
RU (1) RU2126255C1 (no)
WO (1) WO1992020816A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9600847D0 (en) 1996-01-16 1996-03-20 Smithkline Beecham Plc Pharmaceuticals
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
WO2000013708A1 (en) * 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
US6818227B1 (en) 1999-02-08 2004-11-16 Alza Corporation Liposome composition and method for administration of a radiosensitizer
ATE306489T1 (de) 1999-03-08 2005-10-15 Medicure Inc Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel
RU2242970C2 (ru) * 1999-04-02 2004-12-27 Рисерч Дивелопмент Фаундейшн Композиции полиэтиленимин: днк для аэрозольной доставки
AU5922700A (en) * 1999-07-09 2001-01-30 Board Of Regents Of The University Of Nebraska, The Therapy, prevention of recurrence, and diagnosis of colorectal cancer with radiopharmaceuticals
WO2001003682A2 (en) 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
JP2003507418A (ja) 1999-08-24 2003-02-25 メディキュア インターナショナル インコーポレイテッド 心血管疾患とその関連疾患の治療
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
PT1268498E (pt) 2000-02-29 2005-07-29 Medicure Int Inc Fosfonatos cardioprotectores
JP2003528146A (ja) 2000-03-28 2003-09-24 メディキュア インターナショナル インコーポレイテッド 脳血管疾患の治療
US6417204B1 (en) 2000-07-07 2002-07-09 Medicure International Inc. Pyridoxine AMD pyridoxal analogues: cardiovascular therapeutics
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
JP2005508885A (ja) * 2001-07-31 2005-04-07 ザ ステイト オブ オレゴン， アクティング バイ アンド スルー ザ ステイト ボード オブ ハイヤー エデュケイション オン ビハーフ オブ ザ ユニバーシティー オブ オレゴン Ｄｎａメチル化の阻害剤
US7015022B2 (en) * 2002-06-07 2006-03-21 University Of Medicine & Dentistry Of New Jersey Mammalian catalase-dependent oxidation processes and methods for stimulating oxidative activities
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
AU2005259735A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
JP2008517956A (ja) * 2004-10-28 2008-05-29 メディキュア・インターナショナル・インコーポレーテッド 二重の抗血小板性／抗凝固性ピリドキシン類似体
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
PT1928454E (pt) 2005-05-10 2014-12-04 Intermune Inc Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress
US20070149485A1 (en) * 2005-11-28 2007-06-28 Medicure International, Inc. Selected dosage for the treatment of cardiovascular and related pathologies
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
RU2405833C2 (ru) * 2008-12-26 2010-12-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП ГосНИИгенетика) Способ микробиологического синтеза пуринового нуклеозида 5'-аминоимидазол-4-карбоксамидрибозида (аикар) и штамм бактерий bacillus subtilis - продуцент аикар
EP2408306A4 (en) * 2009-03-20 2012-11-07 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
RU2527457C2 (ru) * 2012-09-27 2014-08-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Ингибиторы поли(адф-рибозо)полимеразы-1 человека на основе производных урацила
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
WO2016057699A1 (en) 2014-10-07 2016-04-14 Kinsella Timothy J METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH 5-IODO-2-PYRIMIDINONE-2'-DEOXYRIBOSE (IPdR)
WO2018129514A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
CN118697876A (zh) * 2017-02-09 2024-09-27 完美日光有限公司 用于自闭症谱系障碍药物治疗的方法
EP4003508A1 (en) 2019-07-31 2022-06-01 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895937A (en) * 1982-01-05 1990-01-23 The Research Foundation Of State University Of New York 5-ioso-2-pyrimidinone nucleoside
US4468384A (en) * 1982-01-05 1984-08-28 The Research Foundation Of State University Of New York Method for the inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nucleosides
US4782142A (en) * 1982-01-05 1988-11-01 The Research Foundation Of State University Of New York Novel 5-substituted 2-pyrimidinone nucleosides and methods of use
IE60038B1 (en) * 1986-06-30 1994-05-18 Univ Princeton 4(3H)-oxo-5, 6, 7, 8-tetrahydropyrido-[2, 3-d]pyrimidine derivatives
NZ223880A (en) * 1987-03-16 1991-06-25 Wellcome Found 1-(3-azido-2,3-dideoxy-alpha-d-erythro-pentofuranosyl)-5- methyl-2(1h)-pyrimidinone and pharmaceutically acceptable derivatives thereof and methods of preparation
US4942226A (en) * 1988-12-29 1990-07-17 Merck & Co., Inc. Halogenated pyrimidine nucleosides and their derivatives
ATE161722T1 (de) * 1990-07-19 1998-01-15 Wellcome Found Enzyminaktivatoren
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations

Also Published As

Publication number Publication date
AU1998292A (en) 1992-12-30
NO934059D0 (no) 1993-11-09
NO308884B1 (no) 2000-11-13
HUT67392A (en) 1995-04-28
JPH06507902A (ja) 1994-09-08
AU673803B2 (en) 1996-11-28
WO1992020816A1 (en) 1992-11-26
NO934059L (no) 1993-12-30
NO992273D0 (no) 1999-05-11
IL101879A0 (en) 1992-12-30
IE921581A1 (en) 1992-11-18
EP0586523A1 (en) 1994-03-16
BG98217A (bg) 1995-02-28
KR100245252B1 (ko) 2000-03-02
EP0586523A4 (en) 1995-11-29
IL101879A (en) 1998-06-15
CA2103050A1 (en) 1992-11-16
RU2126255C1 (ru) 1999-02-20
NO306850B1 (no) 2000-01-03
US5728684A (en) 1998-03-17
HU9303237D0 (en) 1994-03-28

Similar Documents

Publication Publication Date Title
NO992273L (no) Anvendelse av et promedikament med en struktur svarende til den av en biopÕvirkende forbindelse som er et uracil eller en uracilbaseanalog
NO941383D0 (no) Stabilisering av humant interferon
NO170260C (no) Fremstilling av oksygen med hoey renhet
MX9204474A (es) Analogos nucleosidos 1,3-oxatiolano.
NO168423C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive bis-(hydroksymetyl) -cyklobutylpuriner og -pyrimidiner
FI952797L (fi) D-vitamiinianalogin uusi kiteinen muoto
FI934366L (fi) Atp-analoger
FI896140A7 (fi) Salpapidin julkisivuseinämärakennetta varten
DK0675724T3 (da) Anvendelse af didesoxynucleosidanaloger til behandling af virale infektioner
NO172986C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte 9h-puriner
DK250089A (da) Immunstimulerende 7-deaza-7-oxa- og 7-deaza-7-thia-analoge af 8-substituerede guanin-9-(1'-beta-d-aldoglycosidyl)-derivater samt deres anvendelse
FI925871L (fi) Menetelmä terapeuttisesti aktiivisten fenyyliguanidiinijohdannaisten valmistamiseksi
NO920082D0 (no) Fremgangsmaate for forbehandling av lignocellulosematerialer foer hoeyutbytte- massedannelse med alkali-peroksyd
FI932759A7 (fi) IL-4:n käyttö rokotteiden immunogeeneihin kohdistuvan immuunireaktion lisäämiseksi
DK282187A (da) Forstoever med tilfoersel af hjaelpeluft
ITBS910107V0 (it) Camminatoio per i primi passi di bambini
DK420185D0 (da) Anvendelse af somatostatinanaloge
FI881821A0 (fi) Nya supraledande kopparoxidfoereningar med skiktstruktur.
ITMI912865A1 (it) Decarbossilazione di alchilcarbonati ad alchileteri
NO922801D0 (no) Fremgangsmaate til fremstilling av suksinylkolinhalogenider
NO168586C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepinon-forbindelser
FI914367A7 (fi) HIV:n inhibointi käyttäen nukleosidijohdannaisten synergististä yhdist elmää
KR910018297U (ko) 에스컬레이터의 내지진형 턱받침부 구조
DK501788A (da) Anvendelse af visse 6-mercaptopuriner til fremstilling af laegemidler
IT8809390A0 (it) Occlusore atto ad ottenere due immagini delle arcate dentarie perfettamente sovrapponibili

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN NOVEMBER 2001